LGR5 and malignant colon neoplasm: The loss of LGR5 in colon cancer cells enhanced resistance to irinotecan and 5-fluorouracil and increased expression of adhesion GPR56, thus the knockdown of GPR56 in multiple colon cancer cell lines led to suppression of tumor growth and decreased drug resistance, which maybe a new target drug for colon cancer.339 Considering its dual role, developing target drugs against it is significant.